GlaxoSmithKline plc (LON:GSK) Rating Reiterated by Shore Capital

Judith Bessette
Agosto 13, 2017

Finally, Koshinski Asset Management Inc. raised its position in GlaxoSmithKline PLC by 5.6% in the first quarter.

Profund Advisors LLC divested its position by shedding 10,030 shares a decrease of 21.3% from 03/31/2017 to 06/30/2017. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company's stock valued at $102,000 after buying an additional 753 shares in the last quarter.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. Insiders have acquired a total of 3,151 shares of company stock valued at $5,054,922 in the last three months. Bronfman E.L. Rothschild L.P. increased its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Profund Advisors LLC claims 37,060 shares valued at $1,598,000. Heritage Trust Co bought a new position in shares of GlaxoSmithKline PLC during the first quarter valued at about $123,000. The brokerage now has a buy rating on the stock. Institutional investors and hedge funds own 8.96% of the company's stock.

GlaxoSmithKline plc (LON GSK) traded down 0.23% during trading on Thursday, hitting GBX 1530.50. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The stock's 50 day moving average price is GBX 1,589.13 and its 200 day moving average price is GBX 1,623.61. The stock has a market capitalization of $94.80 billion, a PE ratio of 37.51 and a beta of 1.03. The pharmaceutical company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

Este fin de semana habrá lluvia de estrellas
Pero, ¿qué sucede para que las veamos de tal manera? Las " Perseidas " son conocidas por ser un fenómeno de alta actividad. Si tenéis la oportunidad de ver este fenómeno, os lo recomendamos porque es una experiencia para todos los sentidos.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a dividend yield of 5.06%. The ex-dividend date is set for Wednesday the 9th of August 2017. GlaxoSmithKline PLC's payout ratio is 197.00%.

ILLEGAL ACTIVITY WARNING: "GlaxoSmithKline PLC (GSK) Shares Sold by Berkeley Capital Partners LLC" was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of worldwide trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/08/13/glaxosmithkline-plc-nysegsk-position-cut-by-financial-architects-inc-updated-updated.html.

Several research analysts have recently commented on the company. Citigroup Inc. reiterated a "neutral" rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. The company now has a consensus rating of Hold and an average price target of $44.67. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a "hold" rating to a "sell" rating in a research report on Monday, April 17th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a "hold" rating to a "buy" rating in a research note on Friday, May 26th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company's stock. The brokerage now has a GBX 1,750 ($23.08) price objective on the stock.

The value of the investment in GlaxoSmithKline PLC went from $1,465,000 to $1,754,000 a change of $289,000 quarter over quarter.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL